Skip to main navigation

Header Nav

Company
Pipeline and Technology
Business Development
Investors
Contact Us

Select Page

Press Releases

Header Nav

Welcome
Financial Information
Financial Fundamentals
Stock Information
- Stock Quote & Chart
- Historic Price Lookup
Filings
- SEC Filings
- Ownership
Corporate Governance
Corporate Presentation
Events
Press Releases
Investor Alerts

Toolkit

Email Alerts
Print Page
Share
RSS Feeds
Contact IR
Search

Press Releases

Year

Aug 23, 2023

Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office

Patent provides protection through late 2039 for drug candidates with potential to improve cardiac function in heart failure patients WARRINGTON, Pa. , Aug. 23, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on

Aug 7, 2023

Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates

Company plans to initiate a Phase 2 SEISMiC extension study of istaroxime in early cardiogenic shock in Q3; Study start-up for a Phase 2 SCAI Stage C cardiogenic shock study underway Completed $12.4 million public offering including full exercise of overallotment option WARRINGTON, Pa. , Aug.

Jun 27, 2023

Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors

WARRINGTON, Pa. , June 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the Company appointed Mark Strobeck , Ph.D.

Jun 12, 2023

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism

This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime and may lead to novel therapies for heart failure WARRINGTON, Pa. , June 12, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology

Jun 5, 2023

Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones

Virtual event to take place on June 14, 2023 at 1:00 pm ET WARRINGTON, Pa. , June 05, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics , Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today

May 15, 2023

Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates

WARRINGTON, Pa. , May 15, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported financial results for the first quarter ended March 31,

Apr 27, 2023

Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime

WARRINGTON, Pa. , April 27, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) is a biotechnology company focused on advancing late-stage interventions for acute cardiovascular disorders of acute heart failure and a lead program studying istaroxime

Apr 24, 2023

Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option

WARRINGTON, Pa. , April 24, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced the closing of its previously announced underwritten

Apr 20, 2023

Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering

WARRINGTON, Pa. , April 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced the pricing of its underwritten public offering

Apr 17, 2023

Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent

Compounds that activate SERCA2a may lead to novel therapies for heart failure WARRINGTON, Pa. , April 17, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular

Pagination

Current page 1
Page 2
Next page
Last page

YM Twitter Feed